Karin Jooss
Chief Tech/Sci/R&D Officer at GRITSTONE BIO, INC.
Net worth: 561 009 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| J. Wolchko | M | 53 | 17 years | |
| Andrew Allen | M | 57 | 9 years | |
| William Rastetter | M | 76 | 13 years | |
| Shefali Agarwal | M | 50 | 5 years | |
| John Mendlein | M | 64 | 17 years | |
| Elaine Jones | M | 69 | 5 years | |
| Naiyer Rizvi | M | 60 | - | |
| Robert Epstein | M | 69 | 10 years | |
| Robert Hershberg | M | 61 | 4 years | |
| James Cho | M | - | 5 years | |
| Yuan Xu | M | 56 | 3 years | |
| Clare Fisher | F | 51 | 2 years | |
| Bahram Valamehr | M | 47 | 6 years | |
| Erin Jones | M | 52 | 8 years | |
| Cindy Tahl | F | 51 | 15 years | |
| Joseph Echevarria | M | 66 | 9 years | |
| Steve Krognes | M | 56 | 6 years | |
| George E. MacDougall | M | - | 3 years | |
| Helen Hobbs | M | 71 | 13 years | |
| Edward Dulac | M | 49 | 4 years | |
| Jim Smith | M | 64 | 10 years | |
| Lawrence Corey | M | 77 | 2 years | |
| Tim Coughlin | M | 57 | 11 years | |
| Michael Lee | M | 45 | 6 years | |
| Shantanu Narayen | M | 60 | 11 years | |
| Bryan Supran | M | - | 8 years | |
| Jerome C. Bressi | M | - | 6 years | |
| Steve Danehy | M | - | 12 years | |
| Jim Beitel | M | - | 7 years | |
| Stacy Lea Proctor | F | - | - | |
| Denis Patrick | M | - | 14 years | |
| Matthew Hawryluk | M | 46 | 9 years | |
| Mikael Dolsten | M | 65 | 15 years | |
| Vassiliki Economides | F | 44 | 3 years | |
| Wen Bo Wang | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William Steere | M | 87 | 28 years | |
| Jeffrey Kindler | M | 68 | 8 years | |
| Amir Nashat | M | 51 | 13 years | |
| Sharon Tetlow | F | 64 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 years |
| Amy Schulman | F | 63 | 6 years | |
| George A. Lorch | M | 82 | 15 years | |
| Yi Ning Zhao | M | 53 | 8 years | |
| Judith Li | F | 40 | 5 years | |
| Marc Tessier-Lavigne | M | 64 | 4 years | |
| Richard Heyman | M | 66 | 7 years | |
| Robert Landry | M | 60 | 4 years | |
| Thomas Woiwode | M | 52 | 6 years | |
| Olivier Brandicourt | M | 68 | 13 years | |
| Peter Svennilson | M | 62 | 4 years | |
| Everett Cunningham | M | 57 | 9 years | |
| Joseph J. Vallner | M | 76 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| John Mascotte | M | 84 | 4 years | |
| Nicholas Simon | M | 67 | 6 years | |
| Michael Brown | M | 82 | 16 years | |
| John J. Schembri | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| M. Anthony Burns | M | 81 | 25 years | |
| William Herbert Gray | M | 82 | 13 years | |
| Robert N. Burt | M | 86 | 11 years | |
| Frances Fergusson | M | 79 | 9 years | |
| Dana George Mead | M | 88 | 12 years | |
| Freda Lewis-Hall | M | 69 | 11 years | |
| Richard Buller | M | 74 | 7 years | |
| François-Maurice Garnier | M | 62 | - | |
| Joann Eisenhart | M | 65 | 12 years | |
| Randy Brenner | M | 51 | 15 years | |
| Cara Cassino | M | 62 | 5 years | |
| Michael Bruce | M | - | 12 years | |
| John Porter | M | 53 | 5 years | |
| Valerie L. Legagneur | F | 50 | 10 years | |
| Margaret McLoughlin | M | 61 | 5 years | |
| Robyn Peters | F | - | 4 years | |
| James Wassil | M | 54 | 4 years | |
| Feng Guo | M | 54 | 11 years | |
| Brian Krex | M | 57 | 9 years | |
| Timothy Sullivan | M | 54 | 2 years | |
| Susan E. Ward | M | - | 2 years | |
| Glenn Miles | M | 58 | 4 years | |
| Thomas Liquard | M | 51 | 4 years | |
| Peter H. Reinhart | M | - | 6 years | |
| David Roth | M | 61 | 4 years | |
| Edmund Harrigan | M | 71 | 12 years | |
| Jennifer J. Rhodes | F | 53 | 6 years | |
| Charles A. Baker | M | 91 | 19 years | |
| Steven Romano | M | 64 | 16 years | |
| John Henderson | M | 79 | - | |
| Corey Goodman | M | 72 | 2 years | |
| Scott R. Shively | M | 67 | 3 years | |
| Angela Rossetti | F | 71 | 5 years | |
| Peter Honig | M | 67 | 7 years | |
| David Simmons | M | 59 | 16 years | |
| Marc Stapley | M | 54 | 3 years | |
| John Thompson | M | 57 | 7 years | |
| Howard Mayer | M | 62 | 7 years | |
| Christine Regan Lindenboom | F | 43 | - | |
| Brenda Mitchell | F | - | - | |
| Anja Guntermann | M | - | 9 years | |
| Julie LeChasseur | F | - | 4 years | |
| Lillian Mu | F | - | 4 years | |
| Michael Pastoor | M | - | 5 years | |
| Kimberly Ma | F | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Karin Jooss
- Personal Network
